Biotech Values

[genisi]

Perifosine in phase I with different dosing regimens as single agent, found no response in CRC. Thus this could be the drug finally found the right combination for right disease setting, or the drug worked in a trial for patients that have certain hidden characteristics/inbalance that cannot be repeated in large trial. I don't think anyone knows at this point.

I'd look for mutations in the Akt pathway that upregulate it. Another direction (which seems to me is the one they took) is to combine with a chemo agent to overcome resistance that is related to the Akt pathway.